Omalizumab (xolair) in treatment resistant bullous pemphigoid

被引：0
|
作者：
Blake, S. [1 ,2 ]
Murrell, D. [1 ,2 ]
机构：
[1] Univ New South Wales, Sydney, NSW, Australia
[2] St George Dept Dermatol, Sydney, NSW, Australia
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2019年 / 60卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [21] Rituximab and Omalizumab Combination Therapy for Bullous Pemphigoid
    Le, Stephanie T.
    Herbert, Samantha
    Haughton, Renee
    Nava, Jordan
    Toussi, Atrin
    Ji-Xu, Antonio
    Maverakis, Emanual
    [J]. JAMA DERMATOLOGY, 2024, 160 (01) : 107 - 109
  • [22] Omalizumab: an underutilized treatment option in bullous pemphigoid patients with co-morbidities
    De, D.
    Kaushik, A.
    Handa, S.
    Mahajan, R.
    Schmidt, E.
    [J]. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (07) : E469 - E472
  • [23] Omalizumab in the treatment of bullous pemphigoid: A single-center series of 15 cases
    Ferhatoglu, Zeynep Altan
    Yucesoy, Sera Nur
    Ak, Tumay
    Demir, Yusuf
    [J]. MEDICINE, 2024, 103 (30)
  • [24] Clinical effect of omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid
    Kwon, Il Joo
    Kim, Taehee
    Yoo, Dae San
    Min, Seoyeon
    Kim, Soo-Chan
    Kim, Jong Hoon
    [J]. JOURNAL OF DERMATOLOGY, 2023, 50 (05): : 705 - 709
  • [25] Dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient
    Navarro-Trivino, Francisco J.
    Llamas-Molina, Jose Maria
    Ayen-Rodriguez, Angela
    Cancela-Diez, Barbara
    Ruiz-Villaverde, Ricardo
    [J]. EUROPEAN JOURNAL OF HOSPITAL PHARMACY, 2021, 28 (06) : 350 - 352
  • [26] Successful management of severe infant bullous pemphigoid with omalizumab
    Dufour, C.
    Souillet, A. L.
    Chaneliere, C.
    Jouen, F.
    Bodemer, C.
    Jullien, D.
    Cambazard, F.
    Joly, P.
    Reix, P.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2012, 166 (05) : 1140 - 1142
  • [27] Biological and Clinical Response to Omalizumab in a Patient with Bullous Pemphigoid
    Menzinger, Sebastien
    Kaya, Gurkan
    Schmidt, Enno
    Fontao, Lionel
    Laffitte, Emmanuel
    [J]. ACTA DERMATO-VENEREOLOGICA, 2018, 98 (02) : 284 - 286
  • [28] Anaphylaxis with Omalizumab (Xolair)
    不详
    [J]. MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2007, 49 (1265): : 60 - 60
  • [29] Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients
    Chebani, Reda
    Lombart, Florian
    Chaby, Guillaume
    Dadban, Ali
    Debarbieux, Sebastien
    Viguier, Manuelle-Anne
    Ingen-Housz-Oro, Saskia
    Pham-Ledard, Anne
    Bedane, Christophe R.
    Picard-Dahan, Catherine
    Berthin, Clemence
    Dereure, Olivier
    Konstantinou, Maria-Polina
    Castel, Marion
    Jouen, Fabienne
    Joly, Pascal
    Seta, Vannina
    Duvert-Lehembre, Sophie
    Le Roux, Christelle
    Quereux, Gaelle
    Sassolas, Bruno
    Brenaut, Emilie
    Sin, Carole
    Richard, Marie-Aleth
    Berard, Frederic
    Giusti, Delphine
    Belmondo, Thibaut
    Gille, Thomas
    Caux, Frederic
    Prost-Squarcioni, Catherine
    Grootenboer-Mignot, Sabine
    Alexandre, Marina
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2024, 190 (02) : 258 - 265
  • [30] Efficacy of omalizumab for the treatment of bullous pemphigoid: Spanish multicentre real-world experience
    Aguado Vazquez, Alvaro
    Estebanez Corrales, Andrea
    Melgosa Ramos, F. Javier
    Mascaro Galy, Jose Manuel
    Fulgencio-Barbarin, Jon
    Bosch Amate, Xavier
    Curto Barredo, Laia
    Blanes-Martinez, Mar
    Ruiz-Villaverde, Ricardo
    Ballester Martinez, Asuncion
    Martin-Torregrosa, Daniel
    Castano Fernandez, Juan Luis
    Cabeza Martinez, Rita
    Perez-Ferriols, Amparo
    Ramos Rodriguez, Daniel
    Boix Vilanova, Julian
    Mele-Ninot, Gemma
    Exposito Serrano, Vicente
    Espana Alonso, Agustin
    Mateu-Puchades, Almudena
    [J]. CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2024, 49 (09) : 1002 - 1006
12345